Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386184 | 0.96 | PDE5A (0.72) | PDE5A | |
| SCHEMBL6382697 | 0.93 | PDE5A (0.72) | PDE5A | |
| SCHEMBL6382064 | 0.88 | PDE5A (0.67) | PDE5A | |
| SCHEMBL6443212 | 0.83 | PDE5A (0.85) | PDE5A | |
| SCHEMBL6444756 | 0.82 | PDE5A (0.88) | PDE5A | |
| SCHEMBL7002710 | 0.82 | PDE5A (0.72) | PDE5A | |
| SCHEMBL3579702 | 0.81 | PDE5A (0.68) | PDE5A | |
| SCHEMBL6384920 | 0.80 | PDE5A (1.00) | PDE5A | |
| SCHEMBL3583701 | 0.80 | PDE5A (0.93) | PDE5A | |
| SCHEMBL3579337 | 0.80 | PDE5A (0.92) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | claimed |
| EP-1241170-A2 | Pyrazolopyrimidine derivatives | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | claimed |
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-6831074-B2 | Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders | PFIZER INC | 2004-12-14 | — | — | US | disclosed |
| US-20020193388-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-12-19 | — | — | US | disclosed |
| EP-1241170-A2 | Pyrazolopyrimidine derivatives | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | PDE5A 1/4885 |
| US-20020193388-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3A | PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.